Does This China Class II Shipment Need a UDI Yet

When an international medical-device distributor, clinical procurement team, or private-label OEM buyer opens an incoming shipping carton of sterile Class II medical devices originating from China on 18 September 2026, the absence or presence of a China Unique Device Identification (UDI) barcode carrier frequently triggers immediate contractual friction. Regulatory affairs managers who rely on English-language consultancy summaries or commercial compliance calendars are increasingly issuing formal deficiency notices claiming that 'China has mandated UDI for all Class II devices by June 2027,' or demanding immediate proofs of NMPA Unique Device Identification Database (UDID) registration under threat of shipment rejection ^{9 10}. Conversely, receiving personnel may accept cartons of high-volume surgical consumables lacking UDI marking based on an unverified vendor statement that Class II implementation does not take effect until 2027. Both approaches reflect a failure to distinguish between the multi-tier statutory rollout enacted by the National Medical Products Administration (NMPA) and the simplified timelines published by commercial third parties.

The operational reality of Chinese medical-device identification is governed by a precise combination of three variables: the statutory variety batch, the labelled manufacturing date on the individual unit packaging, and the destination market of the specific production lot. Evaluating whether a Chinese Class II carton legally requires a UDI barcode today requires auditing the NMPA Registration Certificate (how to verify a Chinese medical device registration certificate), comparing its classification catalogue code against historical and subsequent rollout mandates, and applying the specific exemption rules promulgated by NMPA in early 2026. This guide details the statutory architecture of China's UDI system as of 18 September 2026, analyzes the exact legal differences between the third-batch 103 catalogue and subsequent remaining Class II categories, dismantles prevailing misconceptions regarding registration review failure, and provides a structured incoming-inspection checklist for international buyers.

If a consultancy calendar says all China Class II devices need UDI by 1 June 2027, which clock is that carton actually on?

The most pervasive compliance error encountered in cross-border supply chains on 18 September 2026 is the blanket assertion that 'all Chinese Class II devices must comply with UDI by 1 June 2027.' This formulation, widely syndicated across consultancy newsletters, compliance software blogs, and automated search engine summaries, flattens a complex five-phase rollout into a single future milestone ^{9 10}. A buyer who acts on this flattened narrative will make two symmetric errors: they will accept cartons of Class II devices that have been required to bear UDI since 1 June 2024 as if those cartons still had until 2027, and they will reject remaining-Class-II cartons produced in 2026 that have no statutory obligation to bear a China UDI carrier until production from 1 June 2027.

To determine which statutory clock applies to a specific shipment, one must trace the chronological sequence of NMPA joint implementation announcements:

1. First Batch (Announcement No. 106 of 2020): Listed on the NMPA medical-device announcement index dated 30 September 2020. 2021 No. 114 and 2023 No. 22 restate this batch as 9 categories and 69 Class III varieties, with mandatory implementation for production from 1 January 2021 ^{5 7}. The live 106 HTML was not re-extracted for this article; first-batch facts below follow those official restatements.
2. Second Batch (Announcement No. 114 of 2021): Issued on 13 September 2021 and published on 17 September 2021, this announcement expanded UDI coverage to all remaining Class III medical devices (including Class III in vitro diagnostic reagents) produced from 1 June 2022 ⁵. As of 18 September 2026, all Chinese Class III medical devices manufactured for domestic use have been on mandatory UDI clocks for over 51 months.
3. Third Batch (Announcement No. 22 of 2023): Published on 17 February 2023, this pivotal instrument selected 103 specific Class II device varieties listed in an official annex and mandated that units produced from 1 June 2024 must carry a UDI carrier ^{3 4}. On 18 September 2026, this clock has been in force for exactly 839 days. These 103 varieties do not wait for 2027.
4. Subsequent remaining varieties (Announcement No. 21 of 2026): Issued on 4 March 2026 and published on 13 March 2026, this announcement addresses all remaining device varieties beyond the first, second, and third batches ¹. It establishes two distinct deadlines: remaining Class II devices (including Class II IVDs) and all Class I IVDs produced from 1 June 2027 (256 days away); and remaining Class I non-IVD medical devices produced from 1 June 2029 (987 days away).
5. Pre-Implementation Inventory Exemption: Each of these announcements says medical devices produced prior to the specified implementation date need not carry a UDI carrier ^{1 3 5}.

Consequently, when an auditor asks whether a carton needs a UDI carrier today, the answer does not depend on whether the product is Class II. It depends on whether the product's specific classification catalogue code was enrolled in the 103 third-batch varieties under Announcement 22 of 2023, or whether it belongs to the remaining Class II varieties governed by Announcement 21 of 2026, evaluated against the labelled date of manufacture.

What did 1 June 2024 already change for the 103 Class II varieties in the 2023 No. 22 annex, and how do you match a certificate catalogue code to that annex?

When NMPA, NHC, and NHSA published Announcement No. 22 of 2023 on 17 February 2023 (issued 10 February 2023), they established a targeted implementation strategy for China's vast Class II device sector ³. Rather than subjecting all Class II devices to a single abrupt deadline, the regulators isolated 103 high-volume, clinically sensitive device varieties representing substantial public procurement volume, national healthcare insurance reimbursement expenditures, or specialized clinical intervention risk. The announcement set an uncompromising operational boundary: medical devices within the 103 varieties produced on or after 1 June 2024 must carry a UDI carrier, and their production dates are strictly governed by the product label ^{3 4}.

On 18 September 2026, the 1 June 2024 production clock is not an upcoming milestone; it has been in force for 839 days. If a Class II carton belonging to one of these 103 varieties was produced in August 2024, January 2025, or May 2026 for commercial sale in China, it must carry a compliant UDI carrier on both its smallest sales unit and all higher levels of packaging (excluding logistics transport containers). Accepting such a carton today without a UDI carrier constitutes an incoming quality and compliance failure.

However, international buyers routinely stumble when attempting to identify whether an imported device is included in the 103 varieties. The critical technical trap is relying on English product descriptions, colloquial hospital terminology, or commercial marketing brands. The 103 varieties in the official annex are defined strictly by their Chinese generic names and their six-digit Medical Device Classification Catalogue codes (医疗器械分类目录编码) ⁴. To determine applicability, an auditor must inspect the classification-catalogue code (分类编码) and the approved product name (产品名称) on the official Chinese Medical Device Registration Certificate (how to verify a Chinese medical device registration certificate). Do not treat an English marketing name as the catalogue match.

A line-by-line parsing of the official 103-variety DOCX annex reveals several critical device categories directly relevant to minimally invasive surgery, vascular intervention, and perioperative wound management ⁴:

• 01-02-02 Medical Laser Fiber (医用激光光纤) Class II: Named under chapter 01 (active surgical instruments), 02 (laser surgical equipment and accessories), 02 (医用激光光纤). A Class II fiber is on the 1 June 2024 clock only if the certificate uses this catalogue code ^{4 11}.
• 14-06-05 NPWT Drainage Sponge (负压引流海绵) Class II in part: Named under chapter 14 (infusion, nursing and protective devices), 06 (external devices used with non-vascular catheters / 与非血管内导管配套用体外器械). A dressing SKU is on the 1 June 2024 clock only if the certificate uses this code ^{4 12}.
• 14-06-06 NPWT Sealing Film (负压引流封闭膜) Class II: Named under the same 14-06 family. A drape SKU is on the 1 June 2024 clock only if the certificate uses this code ^{4 12}.
• 14-12-02 Scar Repair Material (疤痕修复材料) Class II: Named under chapter 14, 12 (ostomy and scar-care products / 造口、疤痕护理用品). A scar-gel SKU is on the 1 June 2024 clock only if the certificate uses this code ^{4 14}.
• 02-13-01 Surgical Stapler with Staples (吻合器（带钉）) Class II in part: Named under chapter 02 (passive surgical instruments / 无源手术器械), 13 (suturing and stapling instruments and materials / 吻（缝）合器械及材料), 01 (吻合器（带钉）). A stapler SKU is on the 1 June 2024 clock only if the certificate uses this catalogue code ^{4 13}.
• 01-10-03 Powered Surgical Stapler (电动吻合器) Class II in part: Named under chapter 01 (active surgical instruments), 10 (other surgical equipment), 03 (电动吻合器). A powered stapler is on the 1 June 2024 clock only if the certificate uses this catalogue code ⁴.

Equally critical is what the 103-variety annex does not contain. A comprehensive text search of the official document confirms that the terms prepuce (包皮), circumcision (环切), circumcision device (包皮切割吻合器 / 包皮环切缝合器), and circumcision ring (包皮环切套扎器) appear zero times ⁴. While certain circumcision staplers might be classified by provincial reviewers under generic code 02-13-01 (吻合器（带钉）), dedicated circumcision rings and suturing devices may occupy other classification codes that are not listed in the 103 annex. Therefore, an auditor cannot assume that all surgical stapling devices are inside the 103 list without confirming the exact code on the registration certificate.

What did Announcement 21 of 2026 change on 4 March 2026 for remaining Class II (1 June 2027) and remaining Class I (1 June 2029), and why is production date — not import date or invoice date — the switch?

On 4 March 2026, NMPA, NHC, and NHSA issued Announcement No. 21 of 2026 (subsequently published on the official NMPA portal on 13 March 2026) entitled 'Announcement on Implementing Unique Device Identification for Subsequent Varieties' (关于做好后续品种实施医疗器械唯一标识工作的公告) ¹. Exactly 189 days before 18 September 2026, this announcement set production clocks for remaining varieties beyond Announcements 106 (2020), 114 (2021), and 22 (2023).

Announcement 21 establishes two distinct forward statutory production clocks:

1. Remaining Class II Medical Devices and Class I IVDs (1 June 2027): Section II, item (1) mandates that all Class II medical devices (including Class II in vitro diagnostic reagents) and all Class I in vitro diagnostic reagents produced from 1 June 2027 shall carry a medical device unique identification. Read with the preamble and Section I, that clock covers remaining varieties beyond the first, second, and third batches; it does not reset the 103 already in force since 1 June 2024 ¹. On 18 September 2026, exactly 256 calendar days remain until this statutory cutoff.
2. Remaining Class I Medical Devices (1 June 2029): Section II, item (1) separately mandates that all Class I medical devices produced from 1 June 2029 shall carry a medical device unique identification. Class I IVDs are already on the 2027 clock; remaining Class I non-IVDs are the practical 2029 cohort ¹. On 18 September 2026, exactly 987 calendar days remain until this cutoff.

Announcement 21 does not reprint the 114/22 label sentence. It states that remaining Class II and Class I IVDs produced from 1 June 2027 shall have UDI, and that products of those varieties produced before 1 June 2027 need not (2027年6月1日前生产的上述品种产品可不具有唯一标识); the same produced-from / produced-before split applies to remaining Class I from 1 June 2029 ¹. How to read the production date is stated in Announcements 114 and 22: it is taken from the medical device label (生产日期以医疗器械标签为准) ^{3 5}.

This statutory formulation establishes that the compliance status of a medical device is permanently locked at the moment of manufacturing release. Neither the date of sales order placement, the date of export shipping from a Chinese port, the date of customs clearance in a foreign territory, nor the date of receipt at an overseas warehouse has any bearing on the statutory UDI requirement under Chinese law. If a Chinese manufacturer produces a lot of remaining Class II devices (such as an active negative-pressure wound therapy pump) on 15 May 2027, that entire lot is legally manufactured without a UDI carrier. That lot need not carry a China UDI carrier under Announcement 21's pre-date production rule. Conversely, a unit of the exact same model produced on 2 June 2027 must carry a fully compliant UDI carrier on its unit label and sales carton ¹.

Distributors must take care not to conflate this production-date switch with commercial tender shelf-life requirements (remaining shelf life in sterile-device tenders). A public hospital tender may demand that delivered consumables retain at least 70% or 80% of their labeled shelf life upon delivery. A lot produced in April 2027 may easily fulfill an 80% remaining shelf life clause in late 2027 while having no China UDI production-date obligation under Announcement 21 if the SKU is remaining Class II. Conflating tender commercial terms with statutory UDI illegality is an audit mistake that causes unnecessary shipment rejections.

If the UDI-DI is missing from a 2026 registration file, does Announcement 21 make that a review failure or a certificate revocation?

In the months following the publication of Announcement 21 of 2026, international regulatory consultancies and commercial compliance vendors began circulating aggressive marketing warnings asserting that UDI compliance has become a mandatory prerequisite for premarket approval, and that failing to submit a UDI Device Identifier (UDI-DI) during registration will result in technical review rejection or the outright revocation of Chinese registration certificates ¹⁰. This assertion has filtered into automated AI Overviews, causing widespread anxiety among international manufacturers and private-label buyers.

This assertion is directly contradicted by the explicit statutory text of Announcement No. 21 of 2026. Section II, item (2) outlines the precise mechanics of UDI-DI submission during the premarket registration and filing process:

产品标识不属于备案/注册审查事项，产品标识的单独变化不属于备案/注册变更范畴。
(The product identifier does not belong to filing/registration review items; an isolated change to the product identifier does not fall within the scope of filing/registration alteration.)— NMPA / NHC / NHSA Announcement No. 21 of 2026, Section II, item (2)

This sentence is not novel to Announcement 21; it was carried over from Announcement No. 114 of 2021, Section II, item (2) and Announcement No. 22 of 2023, Section II, item (2) ^{3 5}. The Chinese regulatory authorities deliberately insulated the premarket safety and efficacy technical evaluation from the supply-chain traceability mechanism. When an applicant submits a registration dossier to the Center for Medical Device Evaluation (CMDE) or a provincial evaluation bureau, the technical reviewers evaluate clinical evaluation data, biological safety, bench performance testing, and risk management files. They do not evaluate the UDI-DI, nor do they condition technical approval on UDI assignment.

To properly understand compliance, an auditor must distinguish between the three separate statutory obligations that exist across the lifecycle of a Chinese medical device:

While a missing UDI-DI does not cause premarket registration rejection, it can still matter commercially inside China. Announcement 21, Section II, item (3) requires UDID upload of the smallest sales unit and higher packaging before sale, and bidirectional fill of NHSA insurance-code fields where the device is already in those databases ^{1 8}. Section III, item (7) tells provincial healthcare security departments to strengthen association between NHSA codes and UDI. Hospital tenders can demand a barcode without converting that commercial demand into a statutory review-failure. For an international buyer evaluating an export shipment, confusing domestic reimbursement linkage with certificate revocation is the analytical error.

When does Announcement 15 of 2026 let an export-only or kit-innard shipment skip China UDI, and which importing-country identifier is still required?

On 23 January 2026, NMPA issued Announcement No. 15 of 2026, officially published alongside Announcement 21 on 13 March 2026, entitled 'Announcement on Matters Relating to Implementing Unique Device Identification in Specified Circumstances' (关于特定情形实施医疗器械唯一标识有关事项的公告) ². This crucial regulation formally established statutory exemptions and alternative compliance pathways, eliminating the long-standing regulatory ambiguity surrounding export lots, multi-pack configurations, and specialized procedural kits.

Announcement 15 defines an exemption as an exemption from creating, assigning, and submitting UDI under the 2019 Rules for Unique Device Identification System (医疗器械唯一标识系统规则) ^{2 6}. It sets forth seven primary exemption families:

For international distributors and private-label buyers, Item (五) is the most critical clause in the entire regulation: 'Medical devices manufactured solely for export and not sold or used domestically may be exempt from implementing unique device identification, but shall comply with the requirements of the importing country (region)' (仅用于出口，不在国内销售使用的医疗器械可免于实施医疗器械唯一标识，但应当符合进口国（地区）的要求) ².

This clause harmonizes with Article 2 of the 2019 UDI Rules, which establishes that the Chinese UDI framework applies strictly to medical devices sold and used within the territory of the People's Republic of China ⁶. If an international buyer contracts with a Chinese manufacturer (such as Weihai Medison) for a dedicated OEM or private-label production run destined exclusively for the European Union, the United States, Latin America, or Southeast Asia, Announcement 15 allows exemption from creating, assigning, and submitting a Chinese UDI. Voluntary UDI remains permitted.

However, Announcement 15 explicitly conditions this exemption on compliance with destination country laws. A shipment bound for the United States must comply with 21 CFR 830 (FDA GUDID); a shipment bound for the European Union must comply with MDR Article 27 / IVDR Article 24 (EUDAMED); and shipments bound for Australia or Saudi Arabia must comply with AusUDID or Saudi-DI regulations respectively (who holds the UDI-DI in the US, EU and China). An export-only declaration is not a universal pass from serialization; it is a possible exemption from China's domestic tracking system in favor of the importing market's statutory regime.

Similarly, Item (三) governs procedural kits (sterile procedure kit regulation in the US and EU). In a sterile circumcision procedure kit or a complex NPWT dressing tray, individual sterile components (such as drapes, scalpel blades, or measuring tapes) may be exempt from carrying individual UDI carriers provided that the outer combined kit carries a compliant UDI and the inner components are dedicated exclusively to that procedure tray. If the manufacturer extracts one of those sterile components and sells it as a standalone replenishment SKU, that standalone unit forfeits the Item (三) exemption and must carry its own UDI carrier according to its classification clock.

Worked SKUs: 1470 nm laser fiber, NPWT dressing versus NPWT pump, scar gel, circumcision stapler versus ring, Class III injection needle, Class I Circum-CARE pants

To bridge the gap between statutory text and receiving-dock reality, we examine seven representative medical device product categories spanning minimally invasive urology, vascular surgery, wound therapy, and aesthetic delivery. For each product, we evaluate the NMPA registration classification, hypothesize the 6-digit classification catalogue code, audit its presence in the 103-variety annex, determine the active production clock, and outline the exact verification test required on 18 September 2026.

This matrix highlights the severe danger of relying on high-level device classes or marketing terminology. Consider the stark contrast within a single surgical suite:

• Vascular Laser Suite: A sterile 1470 nm endovenous laser fiber produced in July 2025 for Chinese domestic sale must carry a UDI carrier if the certificate catalogue code is 01-02-02 医用激光光纤, which is named in the 103 annex ^{4 11}. The laser-safety file inside that fiber carton does not include IEC 60601-2-22 capital test data, which belongs to the generator carton (which laser-safety file belongs with a 1470 nm fiber shipment). If that fiber shipment is an export-only run destined for an EU distributor, Announcement 15, Item (五) may exempt it from China UDI, provided it meets the importing country's identifier rule.
• Wound Care Suite: An NPWT drainage dressing kit produced in 2025 must carry a UDI carrier if the certificate uses 14-06-05 负压引流海绵 and/or 14-06-06 负压引流封闭膜, which are named in the 103 annex; the public dressing-kit page does not publish that code or a registration number ^{4 12}. Conversely, the microcomputer-controlled NPWT pump (Class II, Lu Mech Reg. 20182140303) is not those sponge/film annex names; if its certificate is outside the 103, it is remaining Class II under Announcement 21 and need not carry UDI for production before 1 June 2027.
• Circumcision Suite: A Circum-CARE protective garment (Class I, Lu Wei Mech Filing 20190014) need not carry UDI for production before 1 June 2029 under Announcement 21; do not confuse it with annex 14-14 staff PPE ¹. A circumcision ring (Class II, Lu Mech Reg. 20172020238) is a remaining-Class-II hypothesis because 包皮/环切 is not a named annex row, but the certificate code still has to be read. A circumcision stapler (Class II, Lu Mech Reg. 20192020192) might already be on the 1 June 2024 clock if its certificate classifies it under 02-13-01 (吻合器（带钉）) ^{4 13}.
• Aesthetic Suite: A sterile injection needle registered as NMPA Class III is already on the Class III clocks restated by 2021 No. 114 and 2023 No. 22 (first batch from 1 January 2021; remaining Class III from 1 June 2022) ^{5 3}. It does not wait for a Class II 2027 window. The public product page does not publish a Lu Mech Reg. or catalogue code, so this article does not assign the needle to the first 69 varieties versus remaining Class III.

How should a distributor RFQ ask for the labelled production date, the classification-catalogue code, the UDID upload, and the exemption hypothesis?

To prevent receiving-audit failures, tender rejections, or contractual disputes, international medical-device distributors and procurement teams must integrate explicit UDI verification requirements into their Requests for Quotation (RFQs), purchase orders, and quality technical agreements (China GMP Announcement 107 factory qualification). Demanding generic 'full China UDI compliance' invites boilerplate vendor assurances that fail during receiving audits.

A robust, defensible supplier RFQ inquiry must require the Chinese manufacturer to populate five specific data fields prior to purchase order confirmation:

1. Certified Labelled Production Date: The manufacturer must formally declare the anticipated manufacturing release date printed on the primary package and sales carton labels (format: YYYY-MM-DD), accompanied by a commitment that the physical label matches the manufacturing batch record.
2. NMPA Classification Catalogue Code (分类编码): The supplier must provide a clear, unredacted copy of the valid Chinese Medical Device Registration Certificate (中华人民共和国医疗器械注册证) or Class I Filing Certificate (第一类医疗器械备案凭证), identifying the exact 6-digit classification catalogue code (分类编码) on that certificate.
3. Third-Batch Annex Comparison Statement: A signed technical statement affirming whether the provided classification catalogue code is enumerated within the 103 device varieties of Announcement No. 22 of 2023 Annex. If yes, confirmation that production from 1 June 2024 carries a verified UDI carrier; if no, confirmation that the SKU falls under Announcement 21 remaining Class II (1 June 2027) or remaining Class I (1 June 2029).
4. Destination Market & Exemption Declaration: Formal identification of the commercial destination. If the shipment is manufactured solely for export outside China, an explicit invocation of NMPA Announcement No. 15 of 2026, Item (五), accompanied by proof of compliance with the destination territory's UDI regulations (e.g. US FDA GUDID DI, EU EUDAMED Basic UDI-DI).
5. UDID Registration Proof (Domestic Shipments Only): If the shipment is intended for domestic circulation or hospital distribution within the People's Republic of China, an authenticated screenshot or exported record from the public NMPA UDID portal demonstrating that the smallest sales unit UDI-DI and all higher packaging levels have been successfully published ⁸.

By embedding these five specific data fields into procurement contracts, the buyer shifts the burden of proof onto documented statutory evidence rather than verbal sales assurances.

Distributor incoming QA checklist: 103-already vs remaining-2027 vs Class-I-2029 vs Class-III-already vs Announcement 15 exemptions

When an incoming shipment of Chinese medical devices arrives at an overseas receiving warehouse or quarantine facility, the receiving inspection team must execute a systematic six-step decision gate before accepting or rejecting the dossier:

1. Gate 1: Verify Destination Market Scope: Inspect the commercial invoice, outer shipping cartons, and purchase contract. Is this an export-only shipment manufactured exclusively for markets outside China? If YES: Announcement No. 15 of 2026, Item (五) may apply. The shipment may be exempt (可免于) from China UDI creation, assignment, and UDID submission, but must still meet the importing country or region's identifier rule. Proceed to verify destination-market UDI (FDA/MDR) and keep the export-only evidence pack. If NO (intended for China domestic sale/circulation): Proceed to Gate 2.
2. Gate 2: Audit Regulatory Device Classification: Inspect the Chinese Registration Certificate (注册证) or Filing (备案凭证). If Class III: Must carry UDI carrier on all units produced since 1 June 2022 (Announcement 114) or 1 January 2021 (Announcement 106). If Class I non-IVD: No China UDI required until 1 June 2029 (Announcement 21). If Class II: Proceed to Gate 3.
3. Gate 3: Match Catalogue Code to 103 Third-Batch Annex: Compare the classification-catalogue code on the registration certificate against the 2023 No. 22 official annex. Does the 6-digit code match any of the 103 varieties (e.g. 01-02-02 laser fiber, 14-06-05 NPWT sponge, 14-12-02 scar gel)? If YES: The device has been subject to mandatory UDI since 1 June 2024. Proceed to Gate 4. If NO: The device belongs to remaining Class II under Announcement 21. Proceed to Gate 5.
4. Gate 4: Audit Production Date for 103-Batch Devices: Inspect the manufacturing date (生产日期) printed on the unit label and carton. Was the unit manufactured on or after 1 June 2024? If YES: Carton MUST bear a compliant UDI data carrier from an NMPA-recognized issuing agency, and the DI should be uploaded to UDID before China sale. If NO (produced before 1 June 2024): need not carry UDI under the production-date rule; accept dossier.
5. Gate 5: Audit Production Date for Remaining Class II Devices: For devices not in the 103 annex (e.g. active NPWT pumps, circumcision rings), inspect the manufacturing date. On 18 September 2026, any unit manufactured before 1 June 2027 is legally exempt from carrying a China UDI carrier. Accept dossier without China UDI barcode.
6. Gate 6: Screen for Specific Packaging Exemptions: If the product is a multi-pack or procedure kit, verify whether inner items qualify under Announcement 15 Item (一) (multi-unit singles in UDI-coded sales box) or Item (三) (exclusive kit innards). Confirm that components are not sold standalone.

Receiving inspectors must actively watch for six critical file traps that should prompt an immediate dossier send-back:

• Red Flag 1: Accepting a 2025/2026 production lot of a 103-annex Class II device (e.g. laser fiber 01-02-02) without a UDI carrier based on a supplier claiming 'all Class II has until June 2027.' (NON-COMPLIANT: Send back).
• Red Flag 2: Rejecting a 2026 production lot of a remaining Class II device (e.g. an active NPWT pump or circumcision ring) for lacking a China UDI carrier when its statutory clock is 1 June 2027. (IMPROPER REJECTION: Release).
• Red Flag 3: Threatening to cancel a contract because an NMPA registration certificate does not list a UDI-DI, when Announcement 21 explicitly confirms that UDI-DI is not a registration review item. (IMPROPER DEFICIENCY: Clarify).
• Red Flag 4: Claiming Announcement 15 Item (三) procedure kit innard exemption for sterile consumables that the supplier also markets and ships individually outside the kit. (AUDIT FAILURE: Demand UDI).
• Red Flag 5: Assuming Announcement 15 Item (五) export exemption relieves the shipper of US FDA GUDID, EU EUDAMED, or local destination market labelling. (REGULATORY VIOLATION: Demand destination UDI).
• Red Flag 6: Offering a National Healthcare Security Administration (NHSA) medical insurance reimbursement code (医保医用耗材代码) as a legal substitute for NMPA UDID database registration. (COMMERCIAL SUBSTITUTION ERROR: Demand UDID proof).

Where VEMERIX fits — and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. From our modern manufacturing facilities in Weihai, Shandong Province, Medison manufactures and distributes an integrated portfolio of sterile single-use surgical consumables, vascular energy waveguides, and wound management systems.

Our core medical device portfolio holds active National Medical Products Administration (NMPA) registrations and filings across multiple risk classifications:

• Disposable Medical Laser Fiber (1470 nm bare and radial configurations for vascular endovenous laser ablation): NMPA Class II, Lu Mech Reg. 20192010517.
• Disposable NPWT Drainage Dressing Kits (PVA and PU sterile foam dressings, drape films, and suction tubing): NMPA Class II. The public product page does not publish a registration number.
• Disposable Circumcision Staplers (ergonomic anastomat kits for sutureless circumferential resection): NMPA Class II, Lu Mech Reg. 20192020192.
• Scar Reduction Gel (topical medical silicone gel for post-surgical scar management): NMPA Class II, Lu Mech Reg. 20212140526.
• Medical Vacuum NPWT Pump: NMPA Class II, Lu Mech Reg. 20182140303.
• Disposable Circumcision Device (self-detaching circumcision ring): NMPA Class II, Lu Mech Reg. 20172020238.
• Circum-CARE Post-op Protective Pants: NMPA Class I, Lu Wei Mech Filing 20190014.

When international distributors, clinical engineering specialists, and OEM partners evaluate production lots manufactured by Weihai Medison, our technical and regulatory affairs teams provide complete documentation transparency. We assist buyers in auditing labelled manufacturing dates, verifying NMPA certificate classification catalogue codes, establishing whether specific SKUs belong to the 103-variety third batch or remaining Class II schedules, and structuring destination-specific export packs under NMPA Announcement No. 15 of 2026.

However, commercial integrity requires maintaining strict boundaries regarding product truth and regulatory scope:

• No Claim of Universal UDID Listings: This guide does not assert that VEMERIX or Weihai Medison maintains pre-existing public UDID rows for every SKU in our portfolio. UDID listings are maintained and uploaded in strict accordance with statutory rollout schedules and commercial distribution agreements.
• Partner Capital Equipment Separation: The NOVACURE Medical Diode Laser System console (Guo Xie Zhu Zhun 20253011190 held by Guangdong Yunshang) is a partner-supplied Class III capital laser system. VEMERIX manufactures the NMPA-registered 1470 nm single-use laser fiber consumable; we do not manufacture, register, or claim ownership of the NOVACURE console (registering and distributing a single-use endovenous laser fiber).
• Destination Market Primacy for Export: For export-only shipments claiming Announcement 15 Item (五), Chinese domestic UDI carriers may be omitted (可免于). Buyers must confirm that their regulatory dossiers and packaging artwork comply fully with destination market regulations, such as US FDA GUDID or EU MDR requirements. Voluntary China UDI remains permitted.
• Mandatory SKU-Level Verification: Due diligence always begins with the specific product registration certificate. A buyer must never assume that an English marketing name settles the statutory clock; the six-digit classification catalogue code on the Chinese certificate remains the sole legal determinant.

To review technical specifications, inspect active NMPA certificate copies, or discuss OEM/private-label production timelines, explore our product portfolio, review our quality assurance systems, download technical documentation via technical downloads, or initiate a compliance dialogue with our international regulatory team via contact us.

Frequently asked questions

Do all China Class II medical devices need a UDI on 1 June 2027?

No. The formulation that 'all Class II devices need UDI by 1 June 2027' is legally inaccurate. First, 103 specific Class II device varieties listed in the Annex to Announcement No. 22 of 2023 have already been subject to mandatory UDI marking for units produced since 1 June 2024 (over 27 months before today). Second, Announcement No. 21 of 2026 covers remaining varieties beyond 106/114/22; it does not reset those 103 to 2027. Third, the 1 June 2027 date applies to remaining Class II and Class I IVDs produced from that date; products of those varieties produced before 1 June 2027 need not carry a UDI carrier.

If a carton was produced on 15 May 2027, does remaining Class II still need a China UDI?

No. Under Announcement No. 21 of 2026, Section II, item (1), remaining Class II devices (including IVDs) and all Class I IVDs produced from 1 June 2027 shall have UDI (2027年6月1日起生产的全部第二类医疗器械（包括体外诊断试剂）和全部第一类体外诊断试剂应当具有医疗器械唯一标识). Products of those varieties produced before 1 June 2027 need not. Announcements 114 and 22 read the production date from the device label; Announcement 21 uses the same produced-from / produced-before split. A 15 May 2027 remaining-Class-II lot therefore need not carry a China UDI carrier under that text.

Is a UDI-DI a registration-review item under Announcement 21?

No. Announcement No. 21 of 2026, Section II, item (2) expressly states: 'The product identifier does not belong to filing/registration review items; an isolated change to the product identifier does not fall within the scope of filing/registration alteration' (产品标识不属于备案/注册审查事项，产品标识的单独变化不属于备案/注册变更范畴). Technical reviewers evaluating safety and performance dossiers do not review the UDI-DI, and the absence or change of a UDI-DI does not constitute grounds for premarket application rejection or registration certificate revocation.

Does export-only product skip China UDI and also skip FDA GUDID or EUDAMED?

No. Under NMPA Announcement No. 15 of 2026, Item (五), medical devices manufactured solely for export and not sold or used within China may be exempt (可免于) from creating, assigning, and submitting a Chinese UDI under NMPA rules; voluntary UDI remains permitted. The same clause still requires that the device 'shall comply with the requirements of the importing country (region).' A product exported to the United States must comply with US FDA GUDID requirements under 21 CFR 830, and a product exported to the European Union must comply with EU MDR EUDAMED requirements. The export exemption, if claimed, applies only to China's domestic traceability system.

Is a disposable circumcision stapler automatically inside the 103-variety annex because 吻合器（带钉）is listed?

Not automatically. The 2023 No. 22 Annex lists 02-13-01 吻合器（带钉）II类部分 (Surgical stapler with staples, Class II portion). While some circumcision staplers are registered under this generic category, others are registered under specialized urological cutting and suturing codes that are not listed in the 103 annex. Furthermore, terms such as 包皮 (prepuce) or 环切 (circumcision) appear zero times in the annex. An auditor cannot rely on the English word 'stapler'; they must examine the classification-catalogue code (分类编码) on the Chinese Registration Certificate.

Does a Class III injection needle wait until 2027?

No. A sterile single-use injection needle registered as NMPA Class III is already on the Class III production clocks restated by 2021 No. 114 and 2023 No. 22: first batch 9 categories / 69 varieties from 1 January 2021, remaining Class III including IVDs from 1 June 2022. This article does not assign that SKU to the first 69 versus remaining Class III because the public product page does not publish a catalogue code. Either way, Class III devices do not wait for the Class II 2027 remaining-variety clock in Announcement 21.

Does Circum-CARE post-op pants wait until 1 June 2029?

Yes. Circum-CARE Post-op Protective Pants are registered as a Class I medical device under Lu Wei Mech Filing 20190014 (第一类医疗器械备案凭证). Under Announcement No. 21 of 2026, Section II, item (1), remaining Class I medical devices produced from 1 June 2029 shall have UDI. Class I IVDs are on the earlier 2027 clock. Cartons of this Class I SKU produced before 1 June 2029 have no statutory requirement to carry a China UDI carrier.

Does VEMERIX claim a UDID listing in this article?

No. This article is an objective regulatory and incoming-inspection guide analyzing Chinese statutory UDI timelines. It does not publish, assert, or represent that VEMERIX or Weihai Medison holds active public UDID listings for any specific product. UDID listings are executed in strict accordance with statutory rollout milestones and commercial supply agreements. All product claims are governed strictly by the approved data in our product catalog and official registration certificates.